Analyst Rating Update on Supernus Pharmaceuticals (SUPN)

Supernus Pharmaceuticals (SUPN) : 4 brokerage houses believe that Supernus Pharmaceuticals (SUPN) is a Strong Buy at current levels. 2 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Supernus Pharmaceuticals (SUPN). Zacks Investment Research suggests a Buy with a rank of 2.The median of all the 6 Wall Street Analysts endorse the stock as a Buy with a rating of 1.67.

Supernus Pharmaceuticals (SUPN) : The most positive equity analysts on Supernus Pharmaceuticals (SUPN) expects the shares to touch $37, whereas, the least positive believes that the stock will trade at $23 in the short term. The company is covered by 6 Wall Street Brokerage Firms. The average price target for shares are $26.33 with an expected fluctuation of $5.43 from the mean.

For the current week, the company shares have a recommendation consensus of Buy.


Supernus Pharmaceuticals (NASDAQ:SUPN): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $23.98 and $22.13 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $24.00. The buying momentum continued till the end and the stock did not give up its gains. It closed at $22.92, notching a gain of 2.96% for the day. The total traded volume was 1,126,558 . The stock had closed at $22.26 on the previous day.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing products for the treatment of central nervous system diseases. The Company launched its two products in neurology for the treatment of epilepsy, which include Oxtellar XR and Trokendi XR. It is also engaged in developing multiple product candidates in psychiatry to address the medical needs and market opportunities in impulsive aggression across several areas (such as attention deficit hyperactivity disorder (ADHD), autism and bipolar disorder), and ADHD. The Company markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which are indicated for epilepsy in the United States. Its product candidates include Oxtellar XR, Trokendi XR, SPN-810, SPN-812 and SPN-809.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *